# Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors

> **NCT07644650** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Mabsoft Therapeutics (Shanghai) Co., Ltd.** · enrollment: 420 (estimated)

## Conditions studied

- Neoplams

## Interventions

- **BIOLOGICAL:** MST-168

## Key facts

- **NCT ID:** NCT07644650
- **Lead sponsor:** Mabsoft Therapeutics (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2028-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 420 (ESTIMATED)
- **Last updated:** 2026-06-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07644650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07644650, "Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07644650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*